Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.
AstraZeneca spinout Albireo Pharma is moving closer to securing regulatory approval for the company’s treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).
Cerevel Therapeutics began trading on the Nasdaq.
U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.
Abbott’s Miles D. White will be stepping down as chief executive officer on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today’s S&P 100.
London-based GammaDelta Therapeutics announced the spin-out of Adaptate Biotherapeutics, which will focus on developing an immune response to cancer.